Posted by rob on October 24, 2009 under Uncategorized | 
Most mental status deficits in patients with chronic myelogenous leukemia (CML) or primary myelodysplastic syndrome (MDS) precede hematopoietic stem cell transplantation (HSCT) and may improve thereafter, according to research published in the October 1st Cancer. Reuters Health Information (Source: Medscape Medical News Headlines)
More
Posted by rob on under Uncategorized |
Authors: Goldblatt M, Huggins JT, Doelken P, Gurung P, Sahn SA
Dasatanib, which has been approved for rescue therapy for patients with imatinib-resistant chronic myelogenous leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia, is a novel, orally available multitargeted kinase inhibitor of BCR-ABL and SRC family kinases (Quintas-Cardama et al, J Clin Oncol 2007;25:3908-14). It binds to both active and inactive conformations of the ABL gene and is 325 times more potent than imatinib in inhibiting the growth of BCR/ABL cells in vitro (Morelock and Sahn, Chest 1999;116:212-21; Huggins and Sahn, Clin Chest Med 2004;25:141-53). Although dasatinib is a generally well-tolerated drug in the treatment of Philadelphia chromosome positive hematopoetic malignancies, pleural e…
More
Posted by rob on under Uncategorized |
F-18 FDG PET/CT Findings in a Case of Gastric Relapse of Acute Myeloblastic Leukemia.
Clin Nucl Med. 2009 Nov;34(11):788-90
Authors: Suga K, Kawakami Y, Hiyama A, Takeda K, Tanizawa Y, Matsunaga N
An isolated extramedullary relapse of acute myelogenous leukemia (AML) after autologous bone marrow transplantation is uncommon. We report the F-18-fluorodeoxyglucose positron emission tomography-computed tomography (F-18 FDG PET/CT) findings in a 50-year-old man with a gastric relapse of AML. This patient had obtained complete remission (CR) of AML in the lumbar bone marrow by autologous bone marrow transplantation and induction chemoradiotherapy 6 years ago, and CR of the meduallary relapse in the bilateral femoral diaphyses by radiotherapy 2 years ago. Regardless of absence of clinical evidence indicative of relapses of AML, FDG PET/CT scan showed the FDG-avid protrusive mass with the maximum standardized uptake of 6.9 in the gastric fundus, which was histologically diagnosed as a relapse by endoscopic biopsy. After radiotherapy to the stomach, the second FDG PET/CT scan showed the disappearance of this FDG-avid gastric mass, and CR of this lesion was endoscopically confirmed. This case indicates that FDG PET/CT scan may be useful for noninvasively detecting a gastric relapse of AML and for monitoring treatment effect.
PMID: 19851176 [PubMed - in process]
More
